Paid Clinical Trials Wilmington
Discover 137 paid clinical trials in Wilmington, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04181060
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
MILDĀ® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study
Sponsor:
Vertos Medical, Inc.
Location:
Code:
NCT03072927
Conditions
Lumbar Spinal Stenosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MILD
Interspinous Process Decompression
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Sponsor:
AstraZeneca
Location:
Code:
NCT06268873
Conditions
Chronic Kidney Disease and Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Baxdrostat/dapagliflozin
Dapagliflozin in combination with placebo
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Sponsor:
Bellus Health Inc. - a GSK company
Location:
Code:
NCT05599191
Conditions
Refractory Chronic Cough
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BLU-5937
Placebo
A Study Evaluating the Effect of BRIUMVIĀ® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Sponsor:
TG Therapeutics, Inc.
Location:
Code:
NCT06433765
Conditions
Multiple Sclerosis
Eligibility Criteria
Sex: Female
Age: 15 - 50
Healthy Volunteers: Not accepted
Interventions
No intervention
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 Ī¼g
GFF MDI 14.4/9.6 Ī¼g
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT06003426
Conditions
Idiopathic Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
BMS-986278
BMS-986278 Placebo
SUNOSIĀ® (Solriamfetol) Pregnancy Registry
Sponsor:
Axsome Therapeutics, Inc.
Location:
Code:
NCT06413420
Conditions
Narcolepsy
Obstructive Sleep Apnea
Pregnant Women and Their Offspring
Eligibility Criteria
Sex: Female
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Sunosi (solriamfetol)
Other prescription wake-promoting medications or stimulants
No treatment
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Sponsor:
Pfizer
Location:
Code:
NCT06163326
Conditions
Vitiligo
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Ritlecitinib
Ritlecitinib 100 mg
Placebo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
Sponsor:
Pfizer
Location:
Code:
NCT05583526
Conditions
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Ritlecitinib
Placebo